Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of BioSante Pharmaceuticals
So what: At the time of this writing, a whopping 8.5 million shares of BioSante have already changed hands, blowing passed the three-month average volume of roughly 350,000 shares. It's tough to peg exactly what's driving today's enormous rally, but a recent one-year equity financing extension with Kingsbridge Capital, along with positive write-ups from several sources including Seeking Alpha and TheStreet.com, has certainly piqued investor, or better yet, speculative, interest in the stock.
Now what: The few notes I've read on BioSante include insider buying, development deals with the likes of Teva Pharmaceutical, and upcoming key trials (for its therapeutic cancer vaccine and flagship testosterone gel LibiGel) as big reasons to be positive. But while that bull case sounds tempting, BioSante's red ink makes it simply far too much of a gamble, especially after today's huge run-up, for most portfolios. Especially with gorilla rival GlaxoSmithKline paying a more than 5% dividend at the moment, the risks just don't seem worth it.
Interested in more info on BioSante? Add it to your watchlist.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Glaxo is a Motley Fool Global Gains recommendation. The Fool owns shares of and has written covered calls on Glaxo. The Fool owns shares of Teva. Try any of our Foolish newsletter services free for 30 days.
True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Fool's disclosure policy always gets a perfect score.